An unnamed US biopharmaceutical company is to run the rule over ReNeuron Group Plc’s (LON:RENE) exosome drug delivery platform.
Under the terms of the collaboration agreement, the biopharma will explore the use of exosomes as a potential delivery vehicle for synthetic oligonucleotides used in gene therapy.
ReNeuron will provide the exosomes as well as sequence-based know-how while its new partner will provide its expertise in the field of synthetic oligonucleotides to optimise their loading into exosomes.
READ: ReNeuron primed for significant commercial progress
“Exosomes are biological nanoparticles ideally suited to the delivery of nucleic acid-based therapeutics due to their natural occurrence and abundance, their ability to protect their cargo from degradation and their potential for favourable bio-distribution,” said ReNeuron chief executive Olav Hellebø.
“We are delighted to be collaborating with a biopharmaceutical company that has considerable experience in the development of novel oligonucleotide-based therapeutics.”
During the initial feasibility stage there are no cash payments between the parties, but should it prove successful, it is anticipated that a product cross-licensing agreement will be signed by the parties ahead of the pre-clinical and clinical development of the therapeutic candidates.
In early morning trading, ReNeuron shares were 6.2% higher at 51.50p.
-- Adds share price --